Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Nagalaxmi Vemalapally"'
Autor:
Xiaoqing Cheng, Yirui Sun, Maureen Highkin, Nagalaxmi Vemalapally, Xiaohua Jin, Brandon Zhou, Julie L. Prior, Ashley R. Tipton, Shunqiang Li, Anton Iliuk, Samuel Achilefu, Ian S. Hagemann, John R. Edwards, Ron Bose
In metastatic breast cancer, HER2 activating mutations frequently co-occur with mutations in thePIK3CA,TP53, or E-cadherin genes. Of these co-occurring mutations,HER2andPIK3CAmutations are the most prevalent gene pair, with approximately 40% ofHER2mu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1331b3ffa44cac2651a53983bb1b024c
https://doi.org/10.1101/2022.11.09.515796
https://doi.org/10.1101/2022.11.09.515796
Autor:
Xiaoqing Cheng, Yirui Sun, Maureen Highkin, Nagalaxmi Vemalapally, Xiaohua Jin, Brandon Zhou, Julie L. Prior, Ashley R. Tipton, Shunqiang Li, Anton Iliuk, Samuel Achilefu, Ian S. Hagemann, John Edwards, Ron Bose
Publikováno v:
Cancer Research. 83:5778-5778
In metastatic breast cancer, HER2 activating mutations frequently co-occur with mutations in the PIK3CA, TP53, or E-cadherin genes. Of these co-occurring mutations, HER2 and PIK3CA mutations are the most prevalent gene pair, with approximately 40% of
Autor:
Nagalaxmi Vemalapally, Shunqiang Li, Gail Sudlow, Ian S. Hagemann, Yu Tao, Maureen Highkin, Tina Primeau, Samuel Achilefu, Irmina Diala, Ron Bose, Cynthia X. Ma, Jingqin Luo, Richard Bryce, Alshad S. Lalani, Chieh-Yu Lin, Ashley R. Tipton, Xuefeng Gao
Publikováno v:
Cancer Research. 81:PS4-13
Background: HER2 activating mutations occur in 2-5% of metastatic breast cancer (MBC) patients, and three phase II or basket clinical trials have shown that the irreversible pan-HER tyrosine kinase inhibitor, neratinib, has good single agent efficacy
Autor:
Jatinder Gulani Grant Severson, David L. Bolduc, Amandeep Kaur, Nagalaxmi Vemalapally, Maria Moroni
Publikováno v:
RAD Association Journal. 2